Transcept Pharmaceuticals (TSPT) Posts Wider than Expected Q2 Loss of 30c/Share

Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) reported Q2 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1.87 million.

For earnings history and earnings-related data on Transcept Pharmaceuticals, Inc. (TSPT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30